KEYMED BIO-B Secures $45M Milestone Payment from CMG901 Licensing Deal
Clinical Trial Announcement: KEYMED BIO-B announced that AstraZeneca has started a Phase III clinical study for sonesitatug vedotin in combination with capecitabine for treating specific types of advanced gastric cancer.
Milestone Payment: The initiation of the clinical trial has triggered a milestone payment of USD 45 million to KEYMED BIO-B from AstraZeneca, as per their licensing agreement.
Trade with 70% Backtested Accuracy
Analyst Views on 02162
About the author
KEYMED BIO-B Secures $45M Milestone Payment from CMG901 Licensing Deal
Clinical Trial Announcement: KEYMED BIO-B announced that AstraZeneca has started a Phase III clinical study for sonesitatug vedotin in combination with capecitabine for treating specific types of advanced gastric cancer.
Milestone Payment: The initiation of the clinical trial has triggered a milestone payment of USD 45 million to KEYMED BIO-B from AstraZeneca, as per their licensing agreement.
Duoning Biotech Seeks Hong Kong Listing; WUXI BIO is Its Largest Client
Company Listing: Shanghai Duoning Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with Morgan Stanley and Huatai International as joint sponsors.
Clientele and Services: The company provides bioprocess solutions and laboratory products to pharmaceutical companies, CROs, CDMOs, and research institutions, with major clients including top biopharmaceutical firms in China.
Key Clients: WuXi Biologics is highlighted as one of the largest clients and suppliers, along with other notable shareholders such as CSPC Pharma, Akeso, and Keymed Bio-B.
Market Activity: The article notes short selling activity and stock performance for several companies in the sector, indicating market dynamics and investor interest.
<Research>CMSI Forecasts Modest Economic Growth in the US Next Year; Hong Kong Stock Market to Transition Towards Earnings-Driven Performance
US Economic Outlook: The US economy is projected to experience moderate growth next year, supported by the Fed's rate cuts and AI investments, while maintaining a bullish stance on US stocks despite short-term risks.
Hong Kong Stock Market Forecast: Hong Kong stocks are expected to transition from valuation recovery to earnings growth, with liquidity remaining favorable despite challenges in China's economy.
Top Stock Recommendations: CMSI's top stock picks for Q1 2026 include major companies like Alphabet, Meta, Netflix, Tencent, and Alibaba, among others.
Short Selling Data: The report includes detailed short selling data for various stocks, highlighting significant short selling ratios for companies like Geely Auto and BYD Company.
M Stanley Unveils New Asian Thematic Focus List (Table)
Stock Performance Overview: Various companies in the tech and energy sectors are experiencing fluctuations in stock prices, with notable short selling activity reported for several firms, including Li Auto and Hesai Group.
Short Selling Ratios: Significant short selling ratios are observed across multiple companies, with Li Auto showing a high ratio of 38.992%, indicating investor skepticism about its future performance.
Market Trends in Longevity Sector: Companies like Innovent Bio and Heng Rui Pharma are seeing positive stock movements, while others like DualityBio-B are facing declines, reflecting mixed investor sentiment in the longevity sector.
Governance and Investment Insights: Major firms in Singapore, such as Singapore Exchange and CapitaLand Investment, are highlighted, with short selling data indicating varying levels of investor confidence in these companies.
<M Stanley Analysis: Ratings and Target Prices for Biotech Companies (Table)>
Stock Performance Overview: Various stocks such as VISEN PHARMA-B and AKESO show mixed performance, with VISEN PHARMA-B down by 1.138% and AKESO up by 1.002%.
Short Selling Activity: Significant short selling activity is noted across several stocks, including Zai Lab and INNOVENT BIO, with short selling ratios reaching as high as 30.955% for Zai Lab.
Analyst Ratings: Most stocks listed, including INNOVENT BIO and KEYMED BIO-B, are rated as "Outperform," indicating positive expectations from analysts.
Market Trends: The report highlights the top 10 HK stocks with the highest net buys and sells by Southbound funds, reflecting current market trends and investor interests.
<Full-day Takeaway>HSI Closes at 24,902, Up 169 pts; HSTI Closes at 5,521, Up 39 pts; BYD ELECTRONIC Up over 7%; XD INC, LEPU BIO, KEYMED BIO-B, AKESO, SKB BIO-B Hit New Highs; Market Turnover Rises
Market Performance: The Hang Seng Index (HSI) increased by 169 points (0.7%) to close at 24,902, with a market turnover of $229.40 billion. Major stocks like Tencent and CCB saw gains, while others like Xiaomi and Alibaba experienced slight declines.
Notable Stock Movements: BYD Electronic and Lenovo Group had significant increases of 7.7% and 5.1%, respectively, while XD Inc and Lepu Bio achieved remarkable gains of 24.8% and 14.8%, hitting new highs.
KEYMED BIO-B Secures $45M Milestone Payment from CMG901 Licensing Deal
Clinical Trial Announcement: KEYMED BIO-B announced that AstraZeneca has started a Phase III clinical study for sonesitatug vedotin in combination with capecitabine for treating specific types of advanced gastric cancer.
Milestone Payment: The initiation of the clinical trial has triggered a milestone payment of USD 45 million to KEYMED BIO-B from AstraZeneca, as per their licensing agreement.
Duoning Biotech Seeks Hong Kong Listing; WUXI BIO is Its Largest Client
Company Listing: Shanghai Duoning Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with Morgan Stanley and Huatai International as joint sponsors.
Clientele and Services: The company provides bioprocess solutions and laboratory products to pharmaceutical companies, CROs, CDMOs, and research institutions, with major clients including top biopharmaceutical firms in China.
Key Clients: WuXi Biologics is highlighted as one of the largest clients and suppliers, along with other notable shareholders such as CSPC Pharma, Akeso, and Keymed Bio-B.
Market Activity: The article notes short selling activity and stock performance for several companies in the sector, indicating market dynamics and investor interest.
<Research>CMSI Forecasts Modest Economic Growth in the US Next Year; Hong Kong Stock Market to Transition Towards Earnings-Driven Performance
US Economic Outlook: The US economy is projected to experience moderate growth next year, supported by the Fed's rate cuts and AI investments, while maintaining a bullish stance on US stocks despite short-term risks.
Hong Kong Stock Market Forecast: Hong Kong stocks are expected to transition from valuation recovery to earnings growth, with liquidity remaining favorable despite challenges in China's economy.
Top Stock Recommendations: CMSI's top stock picks for Q1 2026 include major companies like Alphabet, Meta, Netflix, Tencent, and Alibaba, among others.
Short Selling Data: The report includes detailed short selling data for various stocks, highlighting significant short selling ratios for companies like Geely Auto and BYD Company.
M Stanley Unveils New Asian Thematic Focus List (Table)
Stock Performance Overview: Various companies in the tech and energy sectors are experiencing fluctuations in stock prices, with notable short selling activity reported for several firms, including Li Auto and Hesai Group.
Short Selling Ratios: Significant short selling ratios are observed across multiple companies, with Li Auto showing a high ratio of 38.992%, indicating investor skepticism about its future performance.
Market Trends in Longevity Sector: Companies like Innovent Bio and Heng Rui Pharma are seeing positive stock movements, while others like DualityBio-B are facing declines, reflecting mixed investor sentiment in the longevity sector.
Governance and Investment Insights: Major firms in Singapore, such as Singapore Exchange and CapitaLand Investment, are highlighted, with short selling data indicating varying levels of investor confidence in these companies.
<M Stanley Analysis: Ratings and Target Prices for Biotech Companies (Table)>
Stock Performance Overview: Various stocks such as VISEN PHARMA-B and AKESO show mixed performance, with VISEN PHARMA-B down by 1.138% and AKESO up by 1.002%.
Short Selling Activity: Significant short selling activity is noted across several stocks, including Zai Lab and INNOVENT BIO, with short selling ratios reaching as high as 30.955% for Zai Lab.
Analyst Ratings: Most stocks listed, including INNOVENT BIO and KEYMED BIO-B, are rated as "Outperform," indicating positive expectations from analysts.
Market Trends: The report highlights the top 10 HK stocks with the highest net buys and sells by Southbound funds, reflecting current market trends and investor interests.
<Full-day Takeaway>HSI Closes at 24,902, Up 169 pts; HSTI Closes at 5,521, Up 39 pts; BYD ELECTRONIC Up over 7%; XD INC, LEPU BIO, KEYMED BIO-B, AKESO, SKB BIO-B Hit New Highs; Market Turnover Rises
Market Performance: The Hang Seng Index (HSI) increased by 169 points (0.7%) to close at 24,902, with a market turnover of $229.40 billion. Major stocks like Tencent and CCB saw gains, while others like Xiaomi and Alibaba experienced slight declines.
Notable Stock Movements: BYD Electronic and Lenovo Group had significant increases of 7.7% and 5.1%, respectively, while XD Inc and Lepu Bio achieved remarkable gains of 24.8% and 14.8%, hitting new highs.
